America’s booming CBD market received a dose of reality this week when the FDA issued a letter to Curaleaf, a major US cannabis and CBD brand, warning that some of its product marketing violates the Federal Food, Drug, and Cosmetic Act.

The FDA has made one thing clear: if you claim your product will heal cancer or alleviate pain, and it is not an FDA-approved drug, the agency will come knocking at your door.

See the original article at Sapling